Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease lymphoma
Phenotype C0149925|small cell lung cancer
Sentences 3
PubMedID- 25676399 Background: besides epidermal growth factor receptor (egfr) mutation, the non-small cell lung cancer (nsclc) of anaplastic lymphoma kinase (alk) rearrangement becomes another important clinical subtype.
PubMedID- 25170012 Fda approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
PubMedID- 22465695 Fluorescence in situ hybridization (fish) is currently used to detect non-small cell lung cancer (nsclc) patients with anaplastic lymphoma kinase (alk) gene rearrangement, who are candidates for alk inhibitor therapy.

Page: 1